Genetic changes and cholesterolemia: Recent Brazilian studies;Alterações genéticas e colesterolemia: Recentes estudos brasileiros

Arquivos Brasileiros de Cardiologia

Volumn 80, Issue 5, 2003, Pages 565-571

  Forti, Neusa ^a   Salazar, Luis A ^b   Diament, Jayme ^b   Giannini, Sergio D ^b   Hirata, Mario H ^b   Hirata, Rosario D C ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR;

BRAZIL; CORONARY ARTERY; GENETICS; HUMAN; HYPERCHOLESTEROLEMIA; REVIEW; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; MALE;

APOLIPOPROTEINS B; FEMALE; GENOTYPE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; POLYMORPHISM, GENETIC; RECEPTORS, LDL;

EID: 21244451558     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Manfroi WC, Marques G, Goldin JR et al. Correlação entre a extensão da aterosclerose coronária e a dislipidemia. Arq Bras Cardiol 1982; 39: 15-19.
2. Giannini SD, Forti N, Góis JM et al. Relações entre valores de HDL-colesterol, dos índices de risco coronário e o grau de aterosclerose avaliado por cinecoronariografia. Arq Bras Cardiol 1985; 44: 305-10.
3. Da Luz PL, Carvalho MEA, Cardoso RHA et al. Incidência de dislipidemia e sua relação com doença arterial coronária em populações brasileiras. Arq Bras Cardiol 1990; 54: 257-64.
4. Ladeia AM, Guimarães AM, Lima JC. Perfil lipídico e doença arterial coronária. Arq Bras Cardiol 1994; 63: 101-6.
5. Forti N, Fukushima J, Giannini SD. Perfil lipídico de indivíduos submetidos à cinecoronariografia em diferentes regiões do Brasil. Arq Bras Cardiol 1997; 68: 333-42.
6. III Diretrizes Brasileiras sobre Dislipidemias e Diretriz de Prevenção de Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol 2001; 77 (supl. III): 1-48.
7. Galton DJ. Genetic determinants of atherosclerosis - related dyslipidemias and their clinical implications. Clin Chem Acta 1997; 257: 181-97.
8. Varret M, Rabes JP, Villeger L et al. Analysis of the 525 point mutation in the human LDL receptor gene database. Atherosclerosis 1999; 144: 182-3.
9. Davignon J, Cohn JS, Mabile L et al. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin Chem Acta 1999; 286: 115-43.
10. Winkelmann BR, Hager J. Genetic variation in coronary heart disease and myocardial infarction: methodological overview and clinical evidence. Pharmacogenomics 2000; 1: 73-94.
11. Jeron A, Hengstenberg C, Engel S et al. The D - allele of the ACE polymorphism is related to increased QT dispersion in 609 patients after myocardial infarction. Eur Heart J 2001; 22: 663-8.
12. Salazar LA, Cavalli SA, Hirata MH et al. Polymorphisms of the low-density lipoprotein receptor gene in Brazilian individuals with heterozygous familial hypercholesterolemia. Braz J Med Biol Res 2000; 33: 1301-4.
13. Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolemia. Atherosclerosis 1993; 104: 1-18.
14. Kotze MJ, Peeters AV, Langenhoven E et al. Phenotypic expression and frequency of familial defective apolipoprotein B-100 in Belgian hypercholesterolemics. Atherosclerosis 1994; 111: 217-25.
15. Pullinguer CR, Hennessy LK, Chaterton JE et al. Familial ligand - defective apolipoprotein B: identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest 1995; 95: 1225-34.
16. Wenham PR, Henderson BG, Penney MD et al. Familial ligand - defective apolipoprotein B-100: detection, biochemical features and haplotype analysis of the R 3531 C mutation in the UK. Atherosclerosis 1997; 129: 185-92.
17. 3500 → Trp mutation in hyperlipidemic Chinese. Clin Chem Acta 1998; 44: 1659-65.
18. Bednarska-Makaruk M, Bisko M, Pulawska MF et al. Familial defective apolipoprotein B-100 in a group of hypercholesterolemic patients in Poland. Identification of a new mutation Thr 3492 Ile in the apolipoprotein B gene. Eur J Hum Genet 2001; 9: 836-42.
19. Gaffney D, Pullinger CR, O'Reilly DS et al. Influence of an asparagine to lysine mutation at aminoacid 3516 of apolipoprotein B on low-density lipoprotein receptor binding. Clin Chem Acta 2002; 321: 113-21.
20. Cavalli SA, Hirata MH, Salazar LA et al. Apolipoprotein B gene polymorphisms: prevalence and impact on serum lipid concentrations in hypercholesterolemic individuals from Brazil. Clin Chem Acta 2000; 302: 189-203.
21. Salazar LA. Influência de alterações genéticas do receptor do LDL no perfil lipídico e na resposta terapêutica de indivíduos brasileiros hipercolesterolêmicos. Tese de doutorado. Faculdade de Ciências Farmacêuticas da Universidade de São Paulo, 2002. 160 p.
22. Ludwig EH, Hopkins PN, Allen A et al. Association of genetic variations in apolipoprotein B with hypercholesterolemia, coronary artery disease and receptor binding of low-density lipoproteins. J Lipid Res 1997; 38: 1361-73.
23. Guzmán ECR, Hirata MH, Quintão ECR et al. Association of the apolipoprotein B gene polymorphism with cholesterol levels and response to fluvastatin in Brazilian individuals with lipid profile of high risk for coronary heart disease. Clin Chem Lab Med 2000; 38: 731-6.
24. Salazar LA, Diament J, Forti N et al. Polymorphisms at the apolipoprotein B-100 gene in Brazilian women in relation to body mass index. Primary prevention program. 5° Congreso Latinoamericano de Aterosclerosis, 1° Congreso de La Sociedad Ibero-latinoamericana de Aterosclerosis, Montevideo, 1999 (Abstract).
25. th International Symposium Multiple Risk Factors in Cardiovascular Disease, Veneza, 1999 (Abstract).
26. Salazar LA, Hirata MH, Giannini SD et al. Seven DNA polymorphisms at the candidate genes of atherosclerosis in Brazilian women with angiographically documented coronary artery disease. Clin Chem Acta 2000; 300: 139-49.
27. Bydlowsky SP, Novak EM, Issa JS et al. DNA polymorphisms of apolipoprotein B and A I - C III - A IV genes in a Brazilian population: a preliminary report. Braz J Med Biol Res 1996; 29: 1269-74.
28. De Pádua Mansur A, Annicchino-Bizachi I, Avakian SD et al. Angiotensin - converting enzyme and apolipoprotein B polymorphisms in coronary artery disease. Am J Cardiol 2000; 85: 1089-93.
29. Scartezini M, Zago MA, Pazin-Filho A et al. Presença do genótipo X-X- / E+E+ do gene da apo B Xba I / Eco R I é marcador de doença coronariana (DAC) em adultos jovens. Arq Bras Cardiol 1999; 73: 5.
30. Machado MO, Hirata MH, Bertolami MC et al. Apo B gene haplotype is associated with lipid profile of higher risk for coronary heart disease in caucasian Brazilian men. J Clin Lab Anal 2001; 15: 19-24.
31. Machado MO, Guzmán ECR, Hirata MH et al. Apolipoprotein B gene polymorphism in ischemic heart disease. Clin Chem 1997; 43 (supl): S 258.
32. Davignon J, Gregg RE, Sing CF. Apoliprotein E polymorphisms and atherosclerosis. Arteriosclerosis 1988; 8: 1-21.
33. Schaeffer EJ, Pedro-Botet J, Brousseau M et al. Genetic factors related to LDL lowering response to statins. XIV International Symposium on Drugs Affecting Lipid Metabolism, New York, 2001 (Abstract book p. 36).
34. Pedro-Botet J, Schaeffer EJ, Bakker-Arkema RG et al. Apolipoprotein E phenotypes affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001; 158: 183-93.
35. th IFCC European Congress of Clinical Chemistry, Brasil, 1997 (Abstract p. 218).
36. Forti N, Salazar LA, Giannini SD et al. Apolipoprotein E isoforms are apparently not related to lipid modification in Brazilian postmenopausal women. Atherosclerosis 1999; 144: 106.
37. Otta MI, Cavalli SA, Hirata RDC et al. Apolipoprotein E genotype frequencies in hypercholesterolemic and diabetic individuals. Clin Chem 1996; 42 (supl): S 297.
38. Cavalli SA, Otta MI, Hirata RDC et al. Apolipoprotein E genotyping in Brazilian normocholesterolemic individuals. Clin Chem 1996; 42 (supl): S 298.
39. Guzmán ECR, Hirata MH, Forti N et al. Polimorfismos dos genes da lipase lipoprotéica e da apolipoproteína E estão associados com a hipertrigliceridemia primária. 9° Congresso do Departamento de Aterosclerose, Sociedade Brasileira de Cardiologia, Natal, 2001 (Abstract p. 39).
40. Villeger L, Abifadel M, Allard D et al. The UMD-LDR database: additions to the software and 490 new entries to the database. Hum Mut 2002; 20: 81-7.
41. Giannini SD, Hirata RDC, Salazar LA et al. HDL-cholesterol (HDL-c) of postmenopausal women is influenced by Hinc II polymorphism of the LDL receptor (LDL-R) gene. Atherosclerosis 1997; 134: 77-8.
42. Salazar LA, Giannini SD, Hirata MH et al. Influence of Ava II and Hinc II polymorphism of the LDL-receptor gene on cholesterol levels in postmenopausal women. JACC 1998; 31 (supl C): 387 C.
43. Salazar LA, Hirata MH, Giannini SD et al. Effects of Ava II and Hinc II polymorphisms at the LDL-receptor gene on serum lipid levels of Brazilian individuals with high risk for coronary heart disease. J Clin Lab Anal 1999; 13: 251-8.
44. Salazar LA, Hirata MH, Forti N et al. Pvu II intron 15 polymorphism at the LDL-receptor gene is associated with differences in serum lipid concentrations in subjects with low and high risk for coronary artery disease from Brazil. Clin Chem Acta 2000; 293: 75-88.
45. Salazar LA, Cavalli SA, Hirata MH et al. Polymorphisms of the low-density lipoprotein receptor gene in Brazilian individuals with heterozygous familial hypercholesterolemia. Braz J Med Biol Res 2000; 33: 1301-4.
46. Salazar LA, Melo CE, Cavalli SA et al. Micrométodo para extração de DNA genômico útil no diagnóstico molecular da hipercolesterolemia familiar. Rev Bras Anal Clin 2001; 33: 111-6.
47. Salazar LA, Hirata MH, Melo CE et al. Five polymorphic variants of the low-density lipoprotein receptor in patients with familial hypercholesterolemia from Brazil. International MEDPED Meeting, Eugendorf, 2002 (Abstract).
48. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mut 1992; 1: 445-6.
49. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In Scriver CR, Beaudet AL, Sly WS, Valle D (ed.). The metabolic basis of inherited disease. New York, McGraw Hill, 1995 p. 1981-2030.
50. Bertolini S, Canatafora A, Averna M et al. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler Thromb Vasc Biol 2000; 20: 1-12.
51. Hobbs HH, Leitersdorf E, Leffert C et al. Evidence for a dominant gene that suppresses hypercholesterolemia in a family with defective low-density lipoprotein receptors. J Clin Invest 1989; 84: 656.
52. Lundhal B, Leren TP, Ose L et al. A functional polymorphism of the microssomal triglyceride transfer protein (MTP-493 G/T) influences lipoprotein phenotype in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 1784-8.
53. Figueiredo MS, Santos JE, Alberto FL et al. High frequency of the Lebanese allele of the LDL-r gene among Brazilian patients with familial hypercholesterolemia. J Med Genet 1992; 29: 813-5.
54. Alberto FL, Figueiredo MS, Zago MA et al. The Lebanese mutation as an important cause of familial hypercholesterolemia in Brazil. Braz J Med Biol Res 1999; 32: 739-45.
55. Salazar LA, Hirata MH, Cavalli SA et al. Molecular basis of familial hypercholesterolemia in Brazil: identification of seven novel LDL-R gene mutations. Hum Mut 2002; 19: 462-3.
56. Salazar LA, Hirata MH, Hirata RD. Increasing the sensitivity of single-strand conformation polymorphism analysis of the LDLR gene mutations in Brazilian patients with familial hypercholesterolemia. Clin Chem Lab Med 2002; 40: 441-5.
57. Cavalli SA, Salazar LA, Hirata MH et al. Polimorfismo da região 5' promotora do gene da CYP 3 A 4 em indivíduos com hipercolesterolemia familiar heterozigótica. Rev Bras Cienc Farmaceut 2001; 37 (supl 1): 8.
58. Guzmán ECR, Hirata MH, Forti N et al. Avaliação do efeito dos polimorfismos Hha I da apolipoproteína E e Pvu II da lípase lipoprotéica em indivíduos com hipertrigliceridemia. Rev Bras Cienc Farmaceut 2001; 37 (supl 1): 7.
59. Hirata RD, Salazar LA, Cavalli AS et al. A method to detect the G 894 T polymorphism of the NOS 3 gene. Clinical validation in familial hypercholesterolemia. Clin Chem Lab Med 2002; 40: 436-40.
60. Salazar LA, Cunha AL, Forti N et al. Genetic markers in women with angiographically documented coronary artery from Brazil. Atherosclerosis 2000; 151: 228.
61. Salazar LA, Cunha AL, Hirata MH et al. Os polimorfismos C 677 T e A 1289 C do gene da M T H F R constituem um fator de risco para doença arterial coronariana em mulheres brasileiras? J Bras Pat Med Lab 2000; 36: 120.
62. Salazar LA, Santos ST, Cunha AA et al. Avaliação do efeito da mutação C 677 T do gene do M T H F R no desenvolvimento precoce de DAC em pacientes brasileiros com hipercolesterolemia familiar. Rev Soc Cardiol Est São Paulo 2001; 11: 66.
63. Hoffmann MM, Winkelmann BR, Wieland H. The significance of genetic polymorphisms in modulating the response to lipid lowering drugs. Pharmacogenomics 2001; 2: 107-121.
64. Corsini A, Bellosta S, Paoletti R. Enzymatic pathways involved in statin metabolism. XIV International Symposium on Drugs Affecting Lipid Metabolism, New York, 2001 (Abstract book p. 36).
65. Miettinen T, Gylling H. ABC G 5/8 genes responsible for serum plant sterol increase during statin treatment. XIV International Symposium on Drugs Affecting Lipid Metabolism, New York, 2001 (Abstract book p. 37).
66. Salazar LA, Hirata MH, Quintão EC et al. Lipid lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the lowdensity lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J Clin Lab Anal 2000; 14: 125-31.
67. Salazar LA, Matsumoto LO, Cavalli SA et al. Polimorfismo do gene da apolipoproteína E influencia a resposta terapêutica às estatinas em indivíduos com hipercolesterolemia familiar. J Bras Patol 2001; 37: 33.
68. Salazar LA, Hirata MH, Forti N et al. Angiotensin I - converting enzyme gene polymorphism and drug response in familial hypercholesterolemia. XIV International Symposium on Drugs Affecting Lipid Metabolism, New York, 2001 (Abstract book p. 37).
69. Salazar LA, Cavalli SA, Hirata MH et al. Variações genéticas no receptor de LDL, ECA e HMG-CoA redutase influenciam a resposta terapêutica na hipercolesterolemia familiar. IX Congresso do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia, Natal, 2001 (Abstract p. 38).
70. Salazar LA, Hirata MH, Forti N et al. Polymorphisms of low-density lipoprotein receptor gene are associated with lipid lowering response in patients with familial hipercolesterolemia. XIV International Symposium on Drugs Affecting Lipid Metabolism, New York, 2001 (Abstract book p. 119).
71. Cavalli SA. Estudo de alterações no gene da enzima CYP 3 A 4 que influenciam a resposta à atorvastatina em indivíduos hipercolesterolêmicos. Doutorado (qualificação), Faculdade de Ciências Farmacêuticas da Universidade de São Paulo, 2002.